Goodwin Procter Guides Biopharma Co.'s $50M IPO Plans
Goodwin Procter LLP-steered biopharmaceutical company Compass Therapeutics set terms for an expected $49.5 million initial public offering on Monday, after a somewhat slower week for IPOs surrounding the U.S. election....To view the full article, register now.
Already a subscriber? Click here to view full article